Gastrointestinal Cancer News

The FDA placed a clinical hold on a phase 1/phase 2 trial designed to evaluate BPX-601 — a chimeric antigen receptor T-cell therapy — followed by rimiducid for patients with previously treated metastatic pancreatic or prostate cancer.

A poor-quality diet appeared associated with an increased risk for early-onset, high-risk distal and rectal adenomas, according to study results published in Journal of the National Cancer Institute.

The FDA granted priority review designation to infigratinib for the treatment of cholangiocarcinoma, according to the agent’s manufacturer.

The University of Texas MD Anderson named 10 early-career faculty members to its fifth annual class of Andrew Sabin Family Fellows.

The FDA granted fast track designation to several agents under investigation for the treatment of patients with certain solid tumors or hematologic malignancies.

Residents of rural areas demonstrated higher rates of early-onset colorectal cancer and greater increases in incidence than residents of urban areas, according to study results published in Cancer.

November is Pancreatic Cancer Awareness Month.

Pancreatic ductal adenocarcinoma historically has been a challenging cancer to treat, and often is not detected until it has progressed and metastasized. Some subtypes respond well to chemotherapy, whereas others are resistant.

Patients with hepatocellular carcinoma who live in rural regions or lower-income households had more advanced disease at diagnosis and higher disease-related mortality than other patients, according to study results published in Cancer.

The FDA granted fast track designation to SRF388 for treatment of certain patients with hepatocellular carcinoma, according to the agent’s manufacturer.